185 related articles for article (PubMed ID: 23099809)
1. Expression of cyclin D1a and D1b as predictive factors for treatment response in colorectal cancer.
Myklebust MP; Li Z; Tran TH; Rui H; Knudsen ES; Elsaleh H; Fluge Ø; Vonen B; Myrvold HE; Leh S; Tveit KM; Pestell RG; Dahl O
Br J Cancer; 2012 Nov; 107(10):1684-91. PubMed ID: 23099809
[TBL] [Abstract][Full Text] [Related]
2. Cyclin D1b in human breast carcinoma and coexpression with cyclin D1a is associated with poor outcome.
Abramson VG; Troxel AB; Feldman M; Mies C; Wang Y; Sherman L; McNally S; Diehl A; Demichele A
Anticancer Res; 2010 Apr; 30(4):1279-85. PubMed ID: 20530440
[TBL] [Abstract][Full Text] [Related]
3. Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy.
Edler D; Glimelius B; Hallström M; Jakobsen A; Johnston PG; Magnusson I; Ragnhammar P; Blomgren H
J Clin Oncol; 2002 Apr; 20(7):1721-8. PubMed ID: 11919227
[TBL] [Abstract][Full Text] [Related]
4. LGR5 and CD133 as prognostic and predictive markers for fluoropyrimidine-based adjuvant chemotherapy in colorectal cancer.
Stanisavljević L; Myklebust MP; Leh S; Dahl O
Acta Oncol; 2016 Dec; 55(12):1425-1433. PubMed ID: 27435662
[TBL] [Abstract][Full Text] [Related]
5. [Interferon-alpha in adjuvant treatment of colorectal carcinoma].
Staib L; Link KH; Henne-Bruns D
Kongressbd Dtsch Ges Chir Kongr; 2002; 119():142-5. PubMed ID: 12704877
[TBL] [Abstract][Full Text] [Related]
6. Identification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer.
Gao S; Tibiche C; Zou J; Zaman N; Trifiro M; O'Connor-McCourt M; Wang E
JAMA Oncol; 2016 Jan; 2(1):37-45. PubMed ID: 26502222
[TBL] [Abstract][Full Text] [Related]
7. The role of Cathepsin S as a marker of prognosis and predictor of chemotherapy benefit in adjuvant CRC: a pilot study.
Gormley JA; Hegarty SM; O'Grady A; Stevenson MR; Burden RE; Barrett HL; Scott CJ; Johnston JA; Wilson RH; Kay EW; Johnston PG; Olwill SA
Br J Cancer; 2011 Nov; 105(10):1487-94. PubMed ID: 21989182
[TBL] [Abstract][Full Text] [Related]
8. Mismatch repair protein expression is an independent prognostic factor in sporadic colorectal cancer.
Ohrling K; Edler D; Hallström M; Ragnhammar P
Acta Oncol; 2010 Aug; 49(6):797-804. PubMed ID: 20307245
[TBL] [Abstract][Full Text] [Related]
9. Increase of survival benefit in advanced resectable colon cancer by extent of adjuvant treatment: results of a randomized trial comparing modulation of 5-FU + levamisole with folinic acid or with interferon-alpha.
Link KH; Kornmann M; Staib L; Redenbacher M; Kron M; Beger HG;
Ann Surg; 2005 Aug; 242(2):178-87. PubMed ID: 16041207
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of S100A4 expression in stage II and III colorectal cancer: results from a population-based series and a randomized phase III study on adjuvant chemotherapy.
Boye K; Jacob H; Frikstad KA; Nesland JM; Maelandsmo GM; Dahl O; Nesbakken A; Flatmark K
Cancer Med; 2016 Aug; 5(8):1840-9. PubMed ID: 27273130
[TBL] [Abstract][Full Text] [Related]
11. Expression of cyclin D1 splice variants is differentially associated with outcome in non-small cell lung cancer patients.
Li R; An SJ; Chen ZH; Zhang GC; Zhu JQ; Nie Q; Xie Z; Guo AL; Mok TS; Wu YL
Hum Pathol; 2008 Dec; 39(12):1792-801. PubMed ID: 18715616
[TBL] [Abstract][Full Text] [Related]
12. A systematic overview of chemotherapy effects in colorectal cancer.
Ragnhammar P; Hafström L; Nygren P; Glimelius B;
Acta Oncol; 2001; 40(2-3):282-308. PubMed ID: 11441937
[TBL] [Abstract][Full Text] [Related]
13. Colorectal cancer in the adjuvant setting: perspectives on treatment and the role of prognostic factors.
Cascinu S; Georgoulias V; Kerr D; Maughan T; Labianca R; Ychou M
Ann Oncol; 2003; 14 Suppl 2():ii25-9. PubMed ID: 12810454
[TBL] [Abstract][Full Text] [Related]
14. A prospective randomised trial to study the role of levamisole and interferon alfa in an adjuvant therapy with 5-FU for stage III colon cancer.
Schippinger W; Jagoditsch M; Sorré C; Gnant M; Steger G; Hausmaninger H; Mlineritsch B; Schaberl-Moser R; Mischinger HJ; Hofbauer F; Holzberger P; Mittlböck M; Jakesz R;
Br J Cancer; 2005 May; 92(9):1655-62. PubMed ID: 15856042
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant regional chemotherapy and systemic chemotherapy versus systemic chemotherapy alone in patients with stage II-III colorectal cancer: a multicentre randomised controlled phase III trial.
Nordlinger B; Rougier P; Arnaud JP; Debois M; Wils J; Ollier JC; Grobost O; Lasser P; Wals J; Lacourt J; Seitz JF; Guimares dos Santos J; Bleiberg H; Mackiewickz R; Conroy T; Bouché O; Morin T; Baila L; van Cutsem E; Bedenne L
Lancet Oncol; 2005 Jul; 6(7):459-68. PubMed ID: 15992694
[TBL] [Abstract][Full Text] [Related]
16. Expression Of Cyclin D1 Protein Isoforms And Its Prognostic Significance In Cervical Cancer.
Gu J; Zhang X; Yang Z; Wang N
Cancer Manag Res; 2019; 11():9073-9083. PubMed ID: 31695498
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant chemotherapy in stage III colon cancer with 5-fluorouracil and levamisole versus 5-fluorouracil and leucovorin.
Dencausse Y; Hartung G; Sturm J; Kopp-Schneider A; Hagmüller E; Wojatschek C; Lindemann H; Fritze D; Queisser W
Onkologie; 2002 Oct; 25(5):426-30. PubMed ID: 12415196
[TBL] [Abstract][Full Text] [Related]
18. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04.
Wolmark N; Rockette H; Mamounas E; Jones J; Wieand S; Wickerham DL; Bear HD; Atkins JN; Dimitrov NV; Glass AG; Fisher ER; Fisher B
J Clin Oncol; 1999 Nov; 17(11):3553-9. PubMed ID: 10550154
[TBL] [Abstract][Full Text] [Related]
19. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy.
Sinicrope FA; Foster NR; Thibodeau SN; Marsoni S; Monges G; Labianca R; Kim GP; Yothers G; Allegra C; Moore MJ; Gallinger S; Sargent DJ
J Natl Cancer Inst; 2011 Jun; 103(11):863-75. PubMed ID: 21597022
[TBL] [Abstract][Full Text] [Related]
20. Nuclear maspin expression as a predictive marker for fluorouracil treatment response in colon cancer.
Hestetun KE; Brydøy M; Myklebust MP; Dahl O
Acta Oncol; 2015 Apr; 54(4):470-9. PubMed ID: 25227897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
